Abivax Sa ADR (ABVX)

$119.10 -4.13 (-3.35%)
Market Cap 10.42B
Revenue (ttm) 0.00
Net Income (ttm) -190.71M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.08
Volume 1,788,754
Avg Vol 1,548,138
Day's Range N/A - N/A
Shares Out 77.93M
Stochastic %K 8%
Beta 0.68
Analysts Strong Sell
Price Target $143.50

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporat...

Industry: Biotechnology
Sector: Healthcare
Phone: 33 1 53 83 09 63
Address:
7-11 boulevard Haussmann, Paris, France
lukeabryant
lukeabryant Jan. 6 at 9:13 PM
$ABVX IF and only IF, the rumors surrounding ABVX are true, I can tell you one thing, ABVX is not leaving the EU.
1 · Reply
1986iamwallstreet
1986iamwallstreet Jan. 6 at 8:53 PM
$ABVX $JNJ
0 · Reply
1986iamwallstreet
1986iamwallstreet Jan. 6 at 8:52 PM
$ABVX $JNJ
0 · Reply
OptionRunners
OptionRunners Jan. 6 at 8:43 PM
$VTYX $LLY $1B+ buyout for $VTYX. $ABVX little roll on the headlines
0 · Reply
Stocktrader3546
Stocktrader3546 Jan. 6 at 7:54 PM
$ABVX this is either going to dump to 80 or straight to 200...lets see what the end of the week brings
0 · Reply
Creisi
Creisi Jan. 6 at 7:43 PM
$ABVX $VALN I think Pfizer, who already own 9% of VALN will Buy the Out this year instead of giving them a 22% Royalty check annually for the Lyme Disease Vaccine which is nearing BLA submission by the 4th quarter of 2026. I don't have any feelers out on this but damn it makes enough sense that I think I will look into it.
0 · Reply
autographic
autographic Jan. 6 at 6:54 PM
$ABVX LETS GO!
0 · Reply
crykoreancry
crykoreancry Jan. 6 at 6:51 PM
$ABVX
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 6 at 6:46 PM
$SLS $ABVX Its BUY TIME Abvx From 8 down to 6 right before it doubled to $10 before the T1 Trading Halt - Gapped Up to $60 on the P3 announcement and Kept on Climbing to $145. Enjoy the Discounts while they Last.
0 · Reply
autographic
autographic Jan. 6 at 6:41 PM
$ABVX $ABVX Just did a peek a boo past VWap after filling 118 gap. Thin top so bulls can easily push back to $125 quickly if $120 holds imo - JPM on horizon!
1 · Reply
Latest News on ABVX
Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy

Dec 23, 2025, 6:41 AM EST - 14 days ago

Abivax: Here's Why Eli Lilly Could Want Its Oral Ulcerative Colitis Therapy

LLY

Abivax to be Added to Nasdaq Biotechnology Index

Dec 18, 2025, 4:05 PM EST - 19 days ago

Abivax to be Added to Nasdaq Biotechnology Index

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Dec 17, 2025, 4:05 PM EST - 20 days ago

Abivax Announces Acceptance of 22 Abstracts Evaluating Obefazimod in Inflammatory Bowel Disease at ECCO 2026, Featuring an Oral Presentation on Preclinical Anti-Fibrotic Findings

Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026

Dec 11, 2025, 4:11 PM EST - 26 days ago

Abivax: "Strong Buy" On Obefazimod New UC Data And Maintenance Results Coming Q2 2026

What's Happening With French Biotech Abivax Stock On Wednesday?

Dec 10, 2025, 12:42 PM EST - 27 days ago

What's Happening With French Biotech Abivax Stock On Wednesday?

French biotech Abivax's shares climb on Eli Lilly bid rumors

Dec 10, 2025, 5:52 AM EST - 27 days ago

French biotech Abivax's shares climb on Eli Lilly bid rumors

LLY

6 Healthcare Stocks With Strong Upward Momentum

Nov 18, 2025, 12:59 PM EST - 7 weeks ago

6 Healthcare Stocks With Strong Upward Momentum

CAH ELAN GH MEDP WGS

Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026

Nov 8, 2025, 7:57 AM EST - 2 months ago

Abivax: Phase 3 Data Was A Home Run, Top Target For M&A In 2026

Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster

Oct 14, 2025, 8:41 AM EDT - 3 months ago

Abivax: Betting Big On The Next Inflammatory Bowel Disease Blockbuster

ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript

Oct 6, 2025, 12:35 PM EDT - 3 months ago

ABIVAX Société Anonyme (ABVX) Shareholder/Analyst Call Transcript

Why Is Abivax Stock Trading Higher On Monday?

Oct 6, 2025, 11:05 AM EDT - 3 months ago

Why Is Abivax Stock Trading Higher On Monday?

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Oct 5, 2025, 11:00 AM EDT - 3 months ago

Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Sep 29, 2025, 4:05 PM EDT - 3 months ago

Abivax Announces Acceptance of Additional Late-Breaking Abstract from the ABTECT Phase 3 Induction Trials to be Presented at 2025 United European Gastroenterology (UEG) Meeting

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Sep 23, 2025, 4:05 PM EDT - 3 months ago

Abivax Announces Presentation of Late-Breaking Abstract for Obefazimod from the ABTECT Phase 3 Induction Trials at 2025 United European Gastroenterology (UEG) Meeting

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Sep 12, 2025, 11:45 AM EDT - 4 months ago

Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

Abivax Presents First Half 2025 Financial Results

Sep 8, 2025, 4:00 PM EDT - 4 months ago

Abivax Presents First Half 2025 Financial Results

How Hedge Funds Won Big on an Obscure Drugmaker

Aug 30, 2025, 5:30 AM EDT - 4 months ago

How Hedge Funds Won Big on an Obscure Drugmaker

2 Logical Mid-Cap Biotech Buyout Targets

Aug 27, 2025, 12:50 PM EDT - 4 months ago

2 Logical Mid-Cap Biotech Buyout Targets

MLTX

Abivax Announces Closing of $747.5 Million Public Offering

Jul 28, 2025, 4:15 PM EDT - 5 months ago

Abivax Announces Closing of $747.5 Million Public Offering

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Jul 25, 2025, 2:00 AM EDT - 5 months ago

Abivax Announces Full Exercise of Underwriters' Option to Purchase Additional ADSs, Bringing Gross Proceeds of Offering to $747.5M (€637.5M)

Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst

Jul 24, 2025, 4:20 PM EDT - 5 months ago

Abivax: Positive Obefazimod Induction Data Leads To Next 44-Week Maintenance Trial Catalyst

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Jul 24, 2025, 8:40 AM EDT - 5 months ago

Abivax announces trading resumption of its ordinary shares on Euronext Paris

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Jul 24, 2025, 8:40 AM EDT - 5 months ago

Abivax Announces Pricing of $650M (€554M) Public Offering of American Depositary Shares

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Jul 24, 2025, 1:30 AM EDT - 5 months ago

Abivax announces temporary trading halt of its ordinary shares on Euronext Paris

Abivax Announces Launch of Public Offering

Jul 23, 2025, 4:15 PM EDT - 5 months ago

Abivax Announces Launch of Public Offering

Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity

Jul 23, 2025, 3:10 PM EDT - 5 months ago

Abivax: Differentiated Phase 3 Data Ignites A Multi-Billion Dollar Opportunity

Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout

Jul 19, 2025, 2:23 AM EDT - 6 months ago

Abivax: Good Entry Point Ahead Of The Mega Catalyst - Phase 3 Data Readout

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Jun 11, 2025, 4:00 PM EDT - 7 months ago

Abivax Announces Results of its June 6, 2025 Annual General Meeting

Abivax Presents First Quarter 2025 Financial Results

Jun 2, 2025, 4:00 PM EDT - 7 months ago

Abivax Presents First Quarter 2025 Financial Results

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

Jun 2, 2025, 11:00 AM EDT - 7 months ago

Biotech Bull Case, ABVX International Interest, JNJ & LLY Options Trades

JNJ LLY

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Apr 29, 2025, 4:05 PM EDT - 9 months ago

Abivax Announces Completion of Enrollment for the Phase 3 ABTECT Trials in Patients with Moderately to Severely Active Ulcerative Colitis

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Apr 22, 2025, 4:05 PM EDT - 9 months ago

Abivax Announces Annual General Meeting Details as Company Advances Toward Key 2025 Value-Driving Milestones

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Apr 22, 2025, 4:00 PM EDT - 9 months ago

Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Mar 26, 2025, 5:05 PM EDT - 10 months ago

Abivax publishes financial reports with the French and U.S. securities regulatory agencies

Abivax Announces Full Year 2024 Financial Results

Mar 24, 2025, 3:30 AM EDT - 10 months ago

Abivax Announces Full Year 2024 Financial Results

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Feb 21, 2025, 2:30 AM EST - 11 months ago

Abivax to Host Key Opinion Leader (KOL) Webcast on March 17, 2025

Abivax Publishes 2025 Financial Calendar

Jan 28, 2025, 2:30 AM EST - 1 year ago

Abivax Publishes 2025 Financial Calendar

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Jan 23, 2025, 4:05 PM EST - 1 year ago

Abivax Announces Presentation of Seven Abstracts for Obefazimod in Ulcerative Colitis at 2025 European Crohn's and Colitis Organization 20th Annual Congress

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Jan 9, 2025, 11:35 AM EST - 1 year ago

Abivax Achieves Key Milestone in Phase 3 ABTECT Trial Enrollment

Abivax Announces a Change to the Composition of its Board of Directors

Dec 23, 2024, 4:05 PM EST - 1 year ago

Abivax Announces a Change to the Composition of its Board of Directors

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Nov 19, 2024, 4:30 PM EST - 1 year ago

Abivax Establishes an At-the-Market (ATM) Program on Nasdaq

Abivax presents third quarter 2024 key financial information

Nov 14, 2024, 4:01 PM EST - 1 year ago

Abivax presents third quarter 2024 key financial information

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Nov 13, 2024, 4:01 PM EST - 1 year ago

Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Oct 7, 2024, 4:01 PM EDT - 1 year ago

Abivax Congratulates Victor Ambros and Gary Ruvkun on Their Nobel Prize for the Discovery of microRNA and its Role in Post-Transcriptional Gene Regulation

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Oct 3, 2024, 4:01 PM EDT - 1 year ago

Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Oct 3, 2024, 2:31 AM EDT - 1 year ago

Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Sep 26, 2024, 2:30 AM EDT - 1 year ago

Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Sep 25, 2024, 4:01 PM EDT - 1 year ago

Abivax Provides Update on Ulcerative Colitis (UC) Combination Therapy Program Strategy and Announces Early Preclinical Combination Data of Obefazimod and Etrasimod in Inflammatory Bowel Disease (IBD) Mouse Model

Abivax presents first-half 2024 financial results

Sep 9, 2024, 4:01 PM EDT - 1 year ago

Abivax presents first-half 2024 financial results

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

Aug 6, 2024, 2:30 AM EDT - 1 year ago

Abivax Announces ABTECT Phase 3 Trial Achieves Key Enrollment Milestone

lukeabryant
lukeabryant Jan. 6 at 9:13 PM
$ABVX IF and only IF, the rumors surrounding ABVX are true, I can tell you one thing, ABVX is not leaving the EU.
1 · Reply
1986iamwallstreet
1986iamwallstreet Jan. 6 at 8:53 PM
$ABVX $JNJ
0 · Reply
1986iamwallstreet
1986iamwallstreet Jan. 6 at 8:52 PM
$ABVX $JNJ
0 · Reply
OptionRunners
OptionRunners Jan. 6 at 8:43 PM
$VTYX $LLY $1B+ buyout for $VTYX. $ABVX little roll on the headlines
0 · Reply
Stocktrader3546
Stocktrader3546 Jan. 6 at 7:54 PM
$ABVX this is either going to dump to 80 or straight to 200...lets see what the end of the week brings
0 · Reply
Creisi
Creisi Jan. 6 at 7:43 PM
$ABVX $VALN I think Pfizer, who already own 9% of VALN will Buy the Out this year instead of giving them a 22% Royalty check annually for the Lyme Disease Vaccine which is nearing BLA submission by the 4th quarter of 2026. I don't have any feelers out on this but damn it makes enough sense that I think I will look into it.
0 · Reply
autographic
autographic Jan. 6 at 6:54 PM
$ABVX LETS GO!
0 · Reply
crykoreancry
crykoreancry Jan. 6 at 6:51 PM
$ABVX
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 6 at 6:46 PM
$SLS $ABVX Its BUY TIME Abvx From 8 down to 6 right before it doubled to $10 before the T1 Trading Halt - Gapped Up to $60 on the P3 announcement and Kept on Climbing to $145. Enjoy the Discounts while they Last.
0 · Reply
autographic
autographic Jan. 6 at 6:41 PM
$ABVX $ABVX Just did a peek a boo past VWap after filling 118 gap. Thin top so bulls can easily push back to $125 quickly if $120 holds imo - JPM on horizon!
1 · Reply
sofranki
sofranki Jan. 6 at 6:21 PM
$ABVX not a buy here yet. Probably got to go around 110s to have another bounce. No news no updates anything can happen. Buy or sell up to you
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 6 at 6:18 PM
$SLS $ABVX Middle of July AbVX share Price crunched from $8 and change down to $6 ... in a day ... it then doubled to $10 right before its P3 Results were announced - T1 Trading Halt and Gap UP to $60 and It Kept on Climbing to a high of $145. Enjoy the Cheap Short Manipulated Shares While you can. Gps Immunotherapy is going to revolution AML treatment. A key distinction between the Approval of Gps Immunotherapy for AML Remission maintenance and most new cancer drugs, is the Existing Number of Patients Currently in Remission Who’ll Immediately be treated - vs treating new patients upon diagnosis. There are 100,000 AML Patients CURRENTLY in Remission inJust the first Setting - who'll be eligible and Benefit from GPs Right out of the GATE - Billions in 2026 Revenue. + 40k-50K AML remission Patients Each year. SLS published GPS Pricing Comps $280K Per Patient in Year 1 $28B TAM Do the MATH on the Value of a $28B TAM.
0 · Reply
EzequielJennings
EzequielJennings Jan. 6 at 5:33 PM
$ABVX A lot of AI claims are just “model does thing.” Peer-reviewed work implies methodology, benchmarking, and reproducibility pressure - which forces better engineering discipline. That discipline is exactly what you want before “commercial deployment at scale” becomes real contracts 😤 company name in bio
0 · Reply
Jgarcapital
Jgarcapital Jan. 6 at 4:17 PM
$ABVX same like every biotech .. will drag it lower and can keep it lower for months same story. When fools were tracking planes. I knew trade was cooked.
1 · Reply
kshonstocks
kshonstocks Jan. 6 at 4:08 PM
adding $ABVX after the pull
0 · Reply
DaxCo
DaxCo Jan. 6 at 4:03 PM
$ABVX $VALN same same but different. What do you think?
0 · Reply
Hognose
Hognose Jan. 6 at 3:11 PM
$ABVX buying some here. 10:30 buying will come in.
0 · Reply
sofranki
sofranki Jan. 6 at 10:00 AM
$ABVX nothing yet. No real news no fake news. What's going on. Is this smart money suppresing to collet on the low or are they dumping.
1 · Reply
Zobzork
Zobzork Jan. 6 at 3:18 AM
$ABVX i cant wait for the Buyout at 10b next week!!!!
0 · Reply
GoodTidings
GoodTidings Jan. 5 at 11:39 PM
$SLS $ABVX I think the normally very cautious Dr. Stergiou now saying very confident and clearly that GPS has caused a paradigm shift shouldn't be taking lightly... The person knows what he is talking about!!! This is not an average breakthrough... It's a paradigm shifting breakthrough which means it will shake the entire cancer therapy industry!!! Oh boy Oh boy what are these shorts in trouble and they don't realise it yet I their pipe dreams!!! 😎😎😎
0 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 5 at 11:33 PM
$SLS $ABVX Simple question: - What if Gps Immunotherapy Really Works? and does get Fda approval... ? - then, the only question is - what is GPS Immunotherapy worth? - Major Note: GPs DOES WORK and is Getting Approval. Updated Valuation: 147M shares float: SLS is worth $40B to Big Pharma 215M Shares -All In $186 per share. https://www.reddit.com/r/10xPennyStocks/comments/1q3lagb/the_recent_market_action_since_the_phase_3_trial/?utm_source=share&utm_medium=web3x&utm_name=web3xcss&utm_term=1&utm_content=share_button
1 · Reply
Gps_100X_ROI_Potential
Gps_100X_ROI_Potential Jan. 5 at 8:51 PM
$SLS $ABVX from $5 and Change to $145 based on its P3 Results - SLS is doing something very Similar. Simple Buy and Hold / Investment Opportunity of a Lifetime - All the Industry Players and Institutional FUNDS KNOW GPS is 100% for Sure Getting FDA Approval and SLS is worth close to $40B to Big Pharma. - Gps immunotherapy will revolutionize Remission Maintenance for multiple Cancer Indications. There are 100,000 AML Patients CURRENTLY in Remission inJust the first Setting - who'll be eligible and Benefit from GPs Right out of the GATE - Billions in 2026 Revenue. + 40k-50K AML remission Patients Each year. SLS published GPS Pricing Comps $280K Per Patient in Year 1 $28B TAM Do the MATH on the Value of a $28B TAM.
1 · Reply